Rodrigues Cláudio, Gomes Ana T P C, Leal Joana, Pereira Pedro, Lopes Pedro C, Mendes Karina, Correia Maria J, Veiga Nélio, Rosa Nuno, Soares Caroline, Ministro Paula
Gastroenterology Department, Viseu Dão-Lafões Health Unit, Viseu, Portugal.
Faculty of Dental Medicine, Center for Interdisciplinary Research in Health, Universidade Católica Portuguesa, Viseu, 3504-505, Portugal.
BMC Oral Health. 2025 May 15;25(1):729. doi: 10.1186/s12903-025-06064-5.
Inflammatory Bowel Disease (IBD), a chronic condition characterized by gastrointestinal inflammation, is influenced by genetic and environmental factors. Emerging evidence suggests a "mouth-gut axis," with the oral cavity reflecting extra-intestinal manifestations of IBD. This study evaluated the oral health status of IBD patients and the potential of salivary calprotectin (SCP) as a biomarker for assessing IBD activity and oral health.
Oral health was assessed in 100 IBD patients [60 with Crohn's disease (CD) and 40 with ulcerative colitis (UC)] and 14 controls. Evaluations included the Decayed, Missing, and Filled Teeth (DMFT) Score, Periodontal Diagnosis and the need for dental or prosthetic treatment. Saliva and stool samples were collected to measure SCP and faecal calprotectin (FCP) levels using the Elia Calprotectin 2 Test. IBD activity was evaluated with FCP, the Harvey-Bradshaw Index for CD, and the Partial Mayo Score for UC.
The DMFT index mean was comparable between IBD patients (mean 7.99, SD 7.73) and controls (mean 10.00, SD 6.49). However, periodontal disease was significantly more prevalent in IBD patients (57% in CD, 70% in UC) than in controls (29%), with severe cases (stages III/IV) more frequent in IBD. Additionally, 89% of IBD patients required dental treatment, and 39% needed prosthetic rehabilitation. SCP levels showed no significant correlation with disease activity or oral health status, while FCP correlated with C-reactive protein and erythrocyte sedimentation rate.
This study underscores the need for improved oral health management in IBD patients and suggests that SCP may not be a reliable biomarker for monitoring IBD or periodontal disease.
Not applicable.
炎症性肠病（IBD）是一种以胃肠道炎症为特征的慢性疾病，受遗传和环境因素影响。新出现的证据表明存在“口-肠轴”，口腔反映了IBD的肠外表现。本研究评估了IBD患者的口腔健康状况以及唾液钙卫蛋白（SCP）作为评估IBD活动和口腔健康生物标志物的潜力。
对100例IBD患者[60例克罗恩病（CD）患者和40例溃疡性结肠炎（UC）患者]和14名对照者进行口腔健康评估。评估包括龋失补牙（DMFT）评分、牙周诊断以及牙科或修复治疗需求。收集唾液和粪便样本，使用Elia钙卫蛋白2检测法测量SCP和粪便钙卫蛋白（FCP）水平。使用FCP、CD的哈维-布拉德肖指数和UC的梅奥部分评分评估IBD活动。
IBD患者（平均7.99，标准差7.73）和对照者（平均10.00，标准差6.49）的DMFT指数均值相当。然而，IBD患者中牙周病的患病率（CD患者中为57%，UC患者中为70%）显著高于对照者（29%），IBD患者中严重病例（III/IV期）更为常见。此外，89%的IBD患者需要牙科治疗，39%需要修复康复。SCP水平与疾病活动或口腔健康状况无显著相关性，而FCP与C反应蛋白和红细胞沉降率相关。
本研究强调了改善IBD患者口腔健康管理的必要性，并表明SCP可能不是监测IBD或牙周病的可靠生物标志物。
不适用。
